1 / 14

Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on  New Medical Therapies. Part 4. Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate,

marcelina
Download Presentation

Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Obesity/Diabetes Epidemic:Adiposopathy & ‘Obesity’- The New Disease!Weight Management in Obesity and DM: Emphasis on  New Medical Therapies Part 4 Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program Cardiometabolic Diabetes Center and Affiliate, Main Line Health System Emeritus, Clinical Associate Professor University of Pennsylvania

  2. ? Explains benefit of Smartphone APPs

  3. DRUGS

  4. Long-Term Pharmacotherapy • Pharmacotherapy typically used to induce weight loss but greater benefit may be for maintenance of weight loss • Use weight loss medication chronically, in same manner as medications for other chronic conditions • Orlistat, a lipase inhibitor: 8% loss at 2 years

  5. Medications • Short-term obesity management • Sympathomimetics (Phentermine, Diethylpropion, Benzphetamine) • Long-term obesity management • Lipase inhibitors (Orlistat) • Recently approved obesity medications • Serotonin agonists (Locaserin)- BELVIQ • Combination agents (Phentermine-topiramate)-QSYMIA

  6. Phentermine (Suprenza) Controlled Type: sympathomimetic Mechanism of action: stimulates the hypothalamus to suppress appetite Year of approval: 1959 FDA approved indication: short-term (< 12 weeks) adjunct to exercise and caloric restriction for BMI ≥ 30 or ≥ 27 in the presence of other risk factors such as hypertension, diabetes or hyperlipidemia Efficacy: 3.6 kg mean weight loss beyond that achieved by placebo at 2-24 weeks (meta-analysis of six placebo-controlled trials; Int J Obes Relat Metab Disord 2002;26:262-73) Adverse effects: risk of dependence and abuse, hypertension, dry mouth, insomnia, tremor, GI disturbance, primary pulmonary hypertension (rare, associated with combined use of fenfluramine in “fen-phen”), valvular heart disease (rare), psychosis (rare) Contraindications: history of CV disease, MAOIs, hyperthyroidism, glaucoma, history of drug abuse, pregnancy, breastfeeding

  7. Orlistat (Xenical, Alli) Type: lipase inhibitor Mechanism of action: inhibits the breakdown of triglycerides into absorbable free fatty acids by lipase enzymes in the stomach and pancreas, resulting in less fat being absorbed Year of approval: 1999 (Xenical – prescription 120 mg TID), 2007 (Alli – OTC 60 mg) FDA approved indication: as an adjunct to a reduced-calorie and low-fat diet for weight loss or to lower the risk of regaining weight after prior weight loss Efficacy: 2.9 kg mean weight loss (Xenical) beyond that achieved by placebo at one year (meta-analysis of 15 trials; Ann Intern Med 2005;142:532-46) Adverse effects: significant diarrhea, fecal incontinence, oily spotting, flatulence, bloating, dyspepsia (all can be reduced with avoidance of fat-rich foods), reduced absorption of fat-soluble vitamins, serious liver injury (rare) Contraindications: malabsorption, cholestasis, impaired liver function, pancreatic disease, pregnancy (added in 2012)

  8. Lorcaserin (Belviq) Type: serotonin agonist Mechanism of action: activates 5-HT2C receptors in the hypothalamus, resulting in increased proopiomelanocortin (POMC) production, which promotes satiety Year of approval: 2012 FDA approved indication: treatment of obesity for adults with BMI ≥ 30 or ≥ 27 in the presence of other risk factors such as hypertension, diabetes or hyperlipidemia Efficacy: 3.6 kg mean weight loss beyond that achieved by placebo (5.8 kg vs. 2.2 kg) at one year (Phase 3 RCT; N Engl J Med 2010; 363:245-256) Adverse effects: headache, nasopharyngitis Contraindications: pregnancy, MAOIs, SSRIs (caution)

  9. Phentermine-topiramate (Qsymia) Controlled Year of approval: 2012 FDA approved indication: chronic weight management, as an adjunct to a reduced-calorie diet and exercise, for BMI ≥ 30 or ≥ 27, in the presence of other risk factors such as hypertension, diabetes or hyperlipidemia Efficacy: 10.7 kg mean weight loss beyond that achieved by placebo (12.6 kg vs. 1.9 kg) at one year (Phase 3 RCT; Obesity (2012); 20 2, 330–342) Adverse effects: tachycardia, insomnia, paresthesias, dizziness, distorted taste sensation, constipation, dry mouth, anxiety, suicidality (rare), acute angle closure glaucoma (rare), metabolic acidosis (rare), increased serum creatinine (rare) Contraindications: pregnancy, glaucoma, hyperthyroidism, MAOIs, history of suicide attempt

  10. Comparative Drug Efficacy

More Related